QQ客服 官方微博 反馈留言

	Cyclooxygenase-2 Genetic Variants Are Predictive of Patient Benefit: Biomarker Analyses from a Randomized Phase II Trial Evaluating Concurrent Chemoradiotherapy with or Without Celecoxib in Unresectable Stage III Non-Small Cell Lung Cancer
	Bi, N.; Liang, J.; Zhou, Z.; Chen, D.; Fu, Z.; Yang, X.; Hui, Z.; Feng, Q.; Xiao, Z.; Lv, J.
	2018
卷号	102期号:3页码:S16-S17
ISSN号	0360-3016
DOI	10.1016/j.ijrobp.2018.06.131
URL标识	查看原文
收录类别	SCIE
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6351623
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Bi, N.,Liang, J.,Zhou, Z.,et al. Cyclooxygenase-2 Genetic Variants Are Predictive of Patient Benefit: Biomarker Analyses from a Randomized Phase II Trial Evaluating Concurrent Chemoradiotherapy with or Without Celecoxib in Unresectable Stage III Non-Small Cell Lung Cancer[J],2018,102(3):S16-S17.
APA	Bi, N..,Liang, J..,Zhou, Z..,Chen, D..,Fu, Z..,...&Wang, L..(2018).Cyclooxygenase-2 Genetic Variants Are Predictive of Patient Benefit: Biomarker Analyses from a Randomized Phase II Trial Evaluating Concurrent Chemoradiotherapy with or Without Celecoxib in Unresectable Stage III Non-Small Cell Lung Cancer.,102(3),S16-S17.
MLA	Bi, N.,et al."Cyclooxygenase-2 Genetic Variants Are Predictive of Patient Benefit: Biomarker Analyses from a Randomized Phase II Trial Evaluating Concurrent Chemoradiotherapy with or Without Celecoxib in Unresectable Stage III Non-Small Cell Lung Cancer".102.3(2018):S16-S17.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。